| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Recently, the ARID1A gene has been identified as a novel tumor suppressor in ovarian clear cell carcinoma (OCCC). The current study was designed to evaluate whether ARID1A was a prognostic factor for progression, survival, and chemoresistance in OCCC. Loss of ARID1A expression was identified in 9 (15.0%) of 60 OCCC samples. Loss of ARID1A correlated with shorter progression-free survival (PFS) (P<0.01) and tended to correlate with shorter overall survival in patients with OCCC treated with platinum-based chemotherapy. When data were stratified for the multivariate analysis, only the loss of ARID1A expression remained a significant predictor of reduced PFS (P=0.03). Tumors with loss of ARID1A were more likely to be chemoresistant than tumors with positive ARID1A (100.0 vs 40.0%, P=0.04). This study demonstrates that loss of ARID1A in OCCC is a negative prognostic factor in patients. Measurement of ARID1A expression may be a method to predict resistance in patients with OCCC.
|
